SCHEMBL2805248

SCHEMBL2805248

COCCCn1c[c]c2ccccc21

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CNR2 P34972 3/20 0.41
CNR1 P21554 1/20 0.41
ALDH1A1 P00352 3/20 0.41
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
PRKACA P17612 1/20 0.35
PRKACG P22612 1/20 0.35
PRKACB P22694 1/20 0.35
RAB9A P51151 3/20 0.35
MAPT P10636 3/20 0.34
NPC1 O15118 2/20 0.34
PTGER4 P35408 1/20 0.34
LMNA P02545 1/20 0.34
TSHR P16473 1/20 0.34
MAPK1 P28482 1/20 0.34
HTT P42858 1/20 0.34
HPGD P15428 3/20 0.34
SMN1; SMN2 Q16637 3/20 0.34
GAA P10253 2/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2784532 0.81 SLC9A1 (0.40) CNR2CNR1ALDH1A1GAAKDM4E
SCHEMBL2948314 0.80 KDM4E (0.38) ALDH1A1RAB9AMAPTNPC1LMNA
SCHEMBL11719143 0.79 SLC9A1 (0.43) CNR2CNR1ALDH1A1CYP2D6CYP2C19
SCHEMBL7093719 0.78 CNR1 (0.38) CNR2CNR1PRKACAPRKACGPRKACB
SCHEMBL6236614 0.78 SLC9A1 (0.37) CNR2CNR1ALDH1A1MAPTLMNA
SCHEMBL6015764 0.77 PRKCA (0.42) CNR1ALDH1A1CYP2D6CYP2C9CYP2C19
SCHEMBL2946816 0.77 CNR2 (0.39) CNR2CNR1PRKACAPRKACGPRKACB
SCHEMBL8082913 0.77 CDK4 (0.38) MAPTLMNATSHRHTTSMN1; SMN2
SCHEMBL5541472 0.75 SIGMAR1 (0.44) HTT
SCHEMBL8135125 0.75 SLC6A4 (0.43) RAB9AMAPTNPC1GAAOPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP claimed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US claimed
EP-2168952-B1 MORPHOLINE DERIVATIVES AS RENIN INHIBITORS MITSUBISHI TANABE PHARMA CORP (JP) 2017-02-15 EP disclosed
US-8975252-B2 Morpholine derivative SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2015-03-10 US disclosed
US-20100240644-A1 MORPHOLINE DERIVATIVE SHANGHAI PHARMACEUTICALS HOLDING CO., LTD. (CN) 2010-09-23 US disclosed
EP-2168952-A1 MORPHOLINE DERIVATIVE Mitsubishi Tanabe Pharma Corporation (JP) 2010-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100240644-A1 MORPHOLINE DERIVATIVE REN, AGTR1, AGTR2 CNR2 612/4885CNR1 520/4885ALDH1A1 2202/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.